Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New antitumor illudin analogues synthesized at U. of California

Sep. 15, 1999

Depsipeptide tested in vitro for B-cell CLL inhibition

Sep. 15, 1999

Cell Pathways continues to investigate apoptosis-promoting compounds for neoplastic diseases

Sep. 14, 1999

MS-275: new benzamide inhibitor of histone deacetylase selected as development candidate

Sep. 14, 1999

Phase II trial expanded for Aronex's renal cell carcinoma product

Sep. 13, 1999

U.S. and Canadian academics design novel prodrug approach to 5-FU chemotherapy

Sep. 10, 1999

Roche to submit sNDA for Xeloda as first-line colorectal cancer therapy

Sep. 10, 1999

Israeli group designs new family of nonpeptide, nonsulfhydryl Ras farnesylation inhibitors

Sep. 9, 1999

Atairgin and Washington State University to develop new therapeutic applications

Sep. 9, 1999

Roberts to market Fareston in the U.S.

Sep. 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...